BioPal Inc is involved with the development, manufacturing and marketing of a new generation of high-precision alternatives to traditional radioactive products, based on anthanide chemistry. BioPAL's core technology is stable isotope labeling of functional probes and neutron activation analysis, a technology that promises to significantly streamline the drug discovery process and improve clinical methods of measuring organ function. BioPAL is also developing innovative products for fluorescence and MRI imaging. The firm specializes in high-precision alternatives to traditional, radiolabeled life science products. Products are labeled with stable (non-radioactive) isotopes and are used in an analogous fashion to their radioactive counterpart. The analysis of stable tracers in samples of interest is performed by BioPAL using neutron activation technology. The firms customers have found this system to be both accurate and easy to use. In many cases, this approach provides information with improved sensitivity and specificity well beyond that achievable by optical markers and traditional radiolabels. BioPalâs product line consist of compounds and materials labeled with these biologically-rare stable isotopes, ideally suited for applications including in-vivo diagnostics using neutron activation (NA) technology, magnetic resonance imaging (MRI), or in-vitro diagnostics using time resolved fluorescent (TRF) technology, electron microscopy (EM) or magnetic cell sorting technology.
